相关实验视频

Updated: Jul 27, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

在肉瘤中药物敏感性和耐药性的景观

Ahmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen

bioRxiv : the preprint server for biology

|June 9, 2023

概括

患者衍生瘤器官 (PDTO) 能够快速查罕见瘤的药物. 这种功能精确医学方法可以确定有效的治疗方法,改善不同类型的肉瘤亚型患者的治疗结果.

科学领域:

在瘤学瘤学.
癌症生物学癌症生物学
药物发现药物发现药物发现

背景情况:

瘤是一种罕见的癌症,有100多种亚型,对临床试验和标准护理治疗开发构成挑战.
患者衍生瘤器官 (PDTO) 为研究个体瘤生物学和药物反应提供了一个有希望的临床前模型.
由于治疗异质性,需要个性化方法来确定对肉瘤患者的有效治疗方法.

结论:

PDTO是了解肉瘤生物学,耐药性和敏感性的宝贵工具.
使用PDTO的功能精准医学计划在罕见癌症的单一机构中是可行的.
这种方法可以指导最佳的药物选择,避免无效的疗法,并改善患者在肉瘤治疗中的结果.

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...